Gilead’s Kite jumps back to the bargaining table to forge $875M pact with a newly-emerged upstart on next-gen cell therapies

John Carroll

Editor & Founder

Just 6 weeks after striking a $2.3 billion deal to develop off-the-shelf cell therapies with Shoreline Biosciences, Gilead sub Kite Pharma has bounced back with another alliance — this time centered on chimeric antigen receptor (CAR)-engineered invariant natural killer T (CAR-iNKT) cells using Appia Bio’s platform for allogeneic cell therapy.

Once again we don’t know what the upfront is here. But Appia’s cash draw, an equity investment and milestones weigh in together at up to $875 million.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

Gilead’s Kite jumps back to the bargaining table to forge $875M pact with a newly-emerged upstart on next-gen cell therapies

John Carroll

Editor & Founder

Unlock this article instantly by becoming a free subscriber.

J&J's AI head jumps to Recursion; Doug Williams resigns as Sana's R&D chief

Rare neuro disorder offers new area for competition, analysts say: #AAN24

Vertex, Alpine’s IgAN drug has Humira-like potential. But not all indications are created equal

CSL Vifor proposes a marketing campaign to settle European Commission investigation

Takeda wins label expansion for subcutaneous Entyvio, creating 'flexibility' for Crohn's patients

Sanofi restructures US commercial vaccines sales force

Gilead’s Kite jumps back to the bar­gain­ing ta­ble to forge $875M pact with a new­ly-emerged up­start on next-gen cell ther­a­pies

John Carroll

Editor & Founder

Unlock this article instantly by becoming a free subscriber.

more like this

J&J's AI head jumps to Re­cur­sion; Doug Williams re­signs as Sana's R&D chief

Rare neu­ro dis­or­der of­fers new area for com­pe­ti­tion, an­a­lysts say: #AAN24

Ver­tex, Alpine’s IgAN drug has Hu­mi­ra-like po­ten­tial. But not all in­di­ca­tions are cre­at­ed equal

CSL Vi­for pro­pos­es a mar­ket­ing cam­paign to set­tle Eu­ro­pean Com­mis­sion in­ves­ti­ga­tion

Take­da wins la­bel ex­pan­sion for sub­cu­ta­neous En­tyvio, cre­at­ing 'flex­i­bil­i­ty' for Crohn's pa­tients

Sanofi re­struc­tures US com­mer­cial vac­cines sales force

Gilead’s Kite jumps back to the bargaining table to forge $875M pact with a newly-emerged upstart on next-gen cell therapies

J&J's AI head jumps to Recursion; Doug Williams resigns as Sana's R&D chief

Rare neuro disorder offers new area for competition, analysts say: #AAN24

Vertex, Alpine’s IgAN drug has Humira-like potential. But not all indications are created equal

CSL Vifor proposes a marketing campaign to settle European Commission investigation

Takeda wins label expansion for subcutaneous Entyvio, creating 'flexibility' for Crohn's patients

Sanofi restructures US commercial vaccines sales force